A real-world study comparing pre-post billed annualized bleed rates and total cost of care among non-inhibitor patients with hemophilia A switching from FVIII prophylaxis to emicizumab-Reference-Cited by-同舟云学术

A real-world study comparing pre-post billed annualized bleed rates and total cost of care among non-inhibitor patients with hemophilia A switching from FVIII prophylaxis to emicizumab

Published:2022-08-03 Issue:10 Volume:38 Page:1685-1693
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Batt Katharine¹^ORCID,Schultz Bob G.²^ORCID,Caicedo Jorge²^ORCID,Hollenbeak Christopher S.³^ORCID,Agrawal Neha⁴^ORCID,Chatterjee Sagnik⁴^ORCID,Bullano Michael²^ORCID

Affiliation:

1. Department of Hematology and Medical Oncology, Wake Forest Baptist School of Medicine, Winston-Salem, NC, USA

2. Outcomes Research, Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA, USA

3. Department of Health Policy and Administration, The Pennsylvania State University, College of Health and Human Development, University Park, PA, USA

4. Complete HEOR Solutions, North Wales, PA, USA

Funder

Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2022.2105072

Reference38 articles.

1. Occurrence of hemophilia in the United States

2. Occurrence rates of haemophilia among males in the United States based on surveillance conducted in specialized haemophilia treatment centres